IBDEI164 ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20887,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,20888,0)
 ;;=204.01^^118^1256^3
 ;;^UTILITY(U,$J,358.3,20888,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20888,1,1,0)
 ;;=1^204.01
 ;;^UTILITY(U,$J,358.3,20888,1,8,0)
 ;;=8^ALL,in Remission
 ;;^UTILITY(U,$J,358.3,20888,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,20889,0)
 ;;=204.10^^118^1256^5
 ;;^UTILITY(U,$J,358.3,20889,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20889,1,1,0)
 ;;=1^204.10
 ;;^UTILITY(U,$J,358.3,20889,1,8,0)
 ;;=8^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,20889,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,20890,0)
 ;;=204.11^^118^1256^7
 ;;^UTILITY(U,$J,358.3,20890,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20890,1,1,0)
 ;;=1^204.11
 ;;^UTILITY(U,$J,358.3,20890,1,8,0)
 ;;=8^CLL,in Remission
 ;;^UTILITY(U,$J,358.3,20890,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,20891,0)
 ;;=201.90^^118^1256^11
 ;;^UTILITY(U,$J,358.3,20891,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20891,1,1,0)
 ;;=1^201.90
 ;;^UTILITY(U,$J,358.3,20891,1,8,0)
 ;;=8^Hodgkin's Lymphoma,Unspec Type
 ;;^UTILITY(U,$J,358.3,20891,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,20892,0)
 ;;=202.00^^118^1256^19
 ;;^UTILITY(U,$J,358.3,20892,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20892,1,1,0)
 ;;=1^202.00
 ;;^UTILITY(U,$J,358.3,20892,1,8,0)
 ;;=8^Lymphoma,Low-Grade (Nodular)
 ;;^UTILITY(U,$J,358.3,20892,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,20893,0)
 ;;=200.20^^118^1256^16
 ;;^UTILITY(U,$J,358.3,20893,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20893,1,1,0)
 ;;=1^200.20
 ;;^UTILITY(U,$J,358.3,20893,1,8,0)
 ;;=8^Lymphoma,Burkitts
 ;;^UTILITY(U,$J,358.3,20893,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,20894,0)
 ;;=202.10^^118^1256^29
 ;;^UTILITY(U,$J,358.3,20894,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20894,1,1,0)
 ;;=1^202.10
 ;;^UTILITY(U,$J,358.3,20894,1,8,0)
 ;;=8^Mycosis Fungoides
 ;;^UTILITY(U,$J,358.3,20894,2)
 ;;=^80360
 ;;^UTILITY(U,$J,358.3,20895,0)
 ;;=273.3^^118^1256^21
 ;;^UTILITY(U,$J,358.3,20895,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20895,1,1,0)
 ;;=1^273.3
 ;;^UTILITY(U,$J,358.3,20895,1,8,0)
 ;;=8^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,20895,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,20896,0)
 ;;=203.00^^118^1256^28
 ;;^UTILITY(U,$J,358.3,20896,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20896,1,1,0)
 ;;=1^203.00
 ;;^UTILITY(U,$J,358.3,20896,1,8,0)
 ;;=8^Multiple Myeloma,W/O Remission
 ;;^UTILITY(U,$J,358.3,20896,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,20897,0)
 ;;=203.01^^118^1256^27
 ;;^UTILITY(U,$J,358.3,20897,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20897,1,1,0)
 ;;=1^203.01
 ;;^UTILITY(U,$J,358.3,20897,1,8,0)
 ;;=8^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,20897,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,20898,0)
 ;;=202.40^^118^1256^8
 ;;^UTILITY(U,$J,358.3,20898,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20898,1,1,0)
 ;;=1^202.40
 ;;^UTILITY(U,$J,358.3,20898,1,8,0)
 ;;=8^Hairy-Cell Leukemia
 ;;^UTILITY(U,$J,358.3,20898,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,20899,0)
 ;;=200.10^^118^1256^18
 ;;^UTILITY(U,$J,358.3,20899,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20899,1,1,0)
 ;;=1^200.10
 ;;^UTILITY(U,$J,358.3,20899,1,8,0)
 ;;=8^Lymphoma,Int/High (Diffuse)
 ;;^UTILITY(U,$J,358.3,20899,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,20900,0)
 ;;=273.1^^118^1256^25
 ;;^UTILITY(U,$J,358.3,20900,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,20900,1,1,0)
 ;;=1^273.1
 ;;^UTILITY(U,$J,358.3,20900,1,8,0)
 ;;=8^Monoclon Paraproteinemia
 ;;^UTILITY(U,$J,358.3,20900,2)
 ;;=^78888
 ;;^UTILITY(U,$J,358.3,20901,0)
 ;;=238.79^^118^1256^20
 ;;^UTILITY(U,$J,358.3,20901,1,0)
 ;;=^358.31IA^8^2
